All In Biotech

Free tool

FAERS Monitor: Xerese

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022436 or its brand name (Xerese, Acyclovir, Hydrocortisone). Reports on generic versions are filed under their own applications.

Reports

40

Serious

24

60% of reports

Hospitalization

5

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pain11
  • inflammation9
  • oedema peripheral9
  • pharyngeal paraesthesia9
  • off label use4
  • drug ineffective3
  • herpes zoster3
  • pain in extremity3
  • application site pain2
  • arthropathy2
  • malaise2
  • myocardial infarction2
  • paraesthesia2
  • rash2
  • abdominal pain1

Reports by year received

View as table
YearReports
20111
20141
20155
20165
20174
20182
20194
20204
202111
20221
20251
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pharyngeal paraesthesiaSignal93000.11684.423,933
inflammationSignal991.751.6721
application site pain247.712.451
oedema peripheralSignal938.821.8297
herpes zosterSignal327.59.252
arthropathy218.94.918
painSignal119.45.777
paraesthesia26.71.75
myocardial infarction26.01.64
pain in extremitySignal35.41.87
rash22.40.61
off label use42.40.92
malaise22.40.61
abdominal pain12.30.30
drug ineffective31.20.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.